Melanotan 2 (MT-2): Benefits, Dosing, Side Effects & What to Know [2026]

Most peptides do one thing well. Melanotan 2 does three things at once: it darkens your skin, ramps up libido, and suppresses appetite.

All from a single subcutaneous injection. All through the same family of melanocortin receptors. That triple action is why MT-2 has one of the most dedicated followings in the peptide community despite never receiving FDA approval.

The research goes back to the mid-1990s at the University of Arizona. The sexual function data was strong enough that a derivative of MT-2 became the FDA-approved drug Vyleesi in 2019. This is the full breakdown on how it works, how to dose it, what the real risks are, and where to source it.

What Is Melanotan 2?

Melanotan 2 is a synthetic cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone (alpha-MSH). Its amino acid sequence is Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-NH₂, with a molecular weight of 1024.18 Da and CAS number 121062-08-6. It binds non-selectively to melanocortin receptors MC1R, MC3R, MC4R, and MC5R.

That non-selective receptor profile is what makes MT-2 unique. It produces multiple effects simultaneously from a single compound:

• Accelerated tanning and UV protection via MC1R activation of melanocytes and eumelanin synthesis
• Increased libido and erectile function via MC4R activation in hypothalamic arousal pathways
• Appetite suppression via MC3R and MC4R signaling in energy homeostasis circuits
• Potential mood and social effects via MC4R-mediated oxytocin release (preclinical data only)

The peptide was developed in the late 1980s at the University of Arizona by researchers Victor Hruby and Mac Hadley. Their original goal was to stimulate the body’s own melanin production to protect fair-skinned populations from UV damage.

Natural alpha-MSH has a plasma half-life of just minutes, making it useless as a drug. MT-2 solves this through five structural modifications that increase potency roughly 1,000-fold and extend the half-life to approximately 1 to 2 hours.

Norleucine replaces methionine at position 4 to prevent oxidation. D-phenylalanine replaces L-phenylalanine at position 7 for enzymatic resistance. The peptide is truncated from 13 to 7 amino acids, cyclized via a lactam bridge, and capped with acetylation and amidation at the termini.

These changes also allow MT-2 to cross the blood-brain barrier. That turned out to matter enormously.

During early testing, a researcher accidentally injected double the intended dose and experienced an 8-hour erection along with severe nausea. That accident redirected the entire research program toward sexual dysfunction.

The sexual function effects were isolated, a metabolite called bremelanotide (PT-141) was developed, and it eventually became the FDA-approved drug Vyleesi for hypoactive sexual desire disorder. MT-2 is the parent compound that made all of that possible.

How Melanotan 2 Works

MT-2’s effects come from activating multiple melanocortin receptors simultaneously. Each receptor pathway explains a different set of effects.

MC1R: Tanning and Pigmentation

MC1R sits on melanocytes in the epidermis. When MT-2 binds it, the signaling cascade runs: Gs-protein activation, increased cAMP, PKA activation, CREB phosphorylation, and upregulation of tyrosinase.

That enzyme converts tyrosine into eumelanin, the brown-black pigment that provides actual UV protection. This is real melanin production, not a cosmetic stain like DHA in spray tans.

MT-2 has sub-nanomolar affinity at MC1R (Ki values reported between 0.27 and 0.67 nM depending on the assay). A 2006 study of 65 fair-skinned Caucasians using the related compound NDP-MSH showed a 41% increase in melanin content and a 59% reduction in thymine dimers.

MC3R: Metabolism and Appetite

MC3R is expressed in the hypothalamus and contributes to energy homeostasis, nutrient partitioning, and fat metabolism. MC3R-knockout mice show increased adiposity without necessarily eating more.

MT-2 activates MC3R at a Ki of approximately 24 to 34 nM. This pathway explains the appetite suppression that people running MT-2 consistently report during loading phases.

MC4R: Sexual Function and Desire

MC4R is responsible for MT-2’s most striking pharmacological effect. It is widely expressed in the hypothalamus, paraventricular nucleus, medial preoptic area, and lumbosacral spinal cord.

When MT-2 activates MC4R centrally, it triggers pro-erectile signaling through neuronal nitric oxide release and simultaneously increases subjective sexual desire. MT-2 shows its highest affinity at MC4R (Ki approximately 2.7 to 6.6 nM).

This is fundamentally different from PDE5 inhibitors like sildenafil. Viagra works peripherally on blood flow. MT-2 works in the brain on both desire and arousal simultaneously.

That distinction matters because MT-2 can produce erections without sexual stimulation, something PDE5 inhibitors cannot do. It also explains the nausea and yawning side effects, since MC4R activation in the brainstem drives those responses.

Melanotan 2 Benefits: What Research and Users Show

The clinical trial data on MT-2 is limited in size but remarkably consistent. The formal human dataset consists of pilot Phase I and Phase II studies totaling fewer than 30 subjects.

That is a real limitation. But the effects observed were strong, statistically significant, and have been replicated thousands of times over in the user community across two decades.

Accelerated Tanning and UV Protection

The foundational tanning study is Dorr et al. (1996), the first Phase I human trial of MT-2. Three male volunteers received 0.01 to 0.03 mg/kg subcutaneously on alternating days.

Two of three showed measurable pigmentation increases after only five low doses.

A larger study using the closely related NDP-MSH (Barnetson et al. 2006, n=65) showed a 41% melanin density increase in fair-skinned subjects. Sunburn cells dropped more than 50%, and thymine dimers in the basal layer dropped 59% (p=0.002).

Dorr et al. (2004) showed the effect is synergistic with UV. Melanotropin-treated subjects had 47% fewer sunburn cells, and tanning persisted at least three weeks longer than sunlight-only controls.

Users consistently describe the MT-2 tan as distinct from a regular sun tan. The common term is “the MT-2 glow.” Because the pigment is actual eumelanin distributed throughout the epidermis, it has a depth and warmth that spray tans don’t match.

Most people report visible darkening by days 4 to 7, with freckles responding first. Significant results typically appear by week 2 to 3.

Response speed varies by Fitzpatrick skin type. Types I and II (fair, burns easily) take the longest, often 3 to 4 weeks. Types III and IV (olive, tans moderately) respond within 1 to 2 weeks.

Types V and VI have high baseline melanin and see minimal additional benefit.

The quality of the tan matters as much as the speed. MT-2 preferentially drives eumelanin synthesis (brown-black, photoprotective) rather than pheomelanin (red-yellow, which can actually generate reactive oxygen species after UV exposure). That biochemical distinction is why the Arizona researchers pursued this approach in the first place.

Sexual Function and Libido

This is where the research evidence is strongest, and it is not close.

Wessells et al. (1998) ran a double-blind, placebo-controlled crossover in 10 men with psychogenic erectile dysfunction. Eight of ten developed erections at 0.025 mg/kg subcutaneously, with mean tip rigidity above 80% lasting 38 minutes versus 3 minutes on placebo (p=0.0045).

A follow-up in 10 men with organic ED (Wessells et al. 2000) showed MT-2 triggered erections in 12 of 19 injections versus 1 of 21 on placebo. Even in men with vascular impairment, the central mechanism produced results.

The pooled analysis found 85% of subjects experienced erections without any sexual stimulation. Sixty-eight percent reported increased desire compared to 19% on placebo (p<0.01).

These findings led Palatin Technologies to develop bremelanotide (PT-141), which completed Phase III trials in over 1,200 women and won FDA approval as Vyleesi in June 2019. Users running MT-2 for tanning consistently report heightened libido as a prominent effect.

Appetite Suppression and Fat Loss

MC4R is one of the most important regulators of energy homeostasis. Loss-of-function MC4R mutations cause the most common form of monogenic obesity, affecting 1 to 2.5% of individuals with a BMI over 30.

Animal research shows potent anorexic effects. University of Florida data found central MT-2 infusion in rats produced abdominal fat pads 40% smaller than controls, with effects persisting independently of caloric restriction.

In humans, appetite suppression was documented as a side effect in all MT-2 trials, though no dedicated weight loss study has been conducted. People running MT-2 commonly report significant appetite reduction during loading. For those interested in peptide approaches to body composition, our guide to peptides for fat loss covers compounds where that is the primary indication.

Potential Mood Effects

Preclinical research has identified some interesting signals here. MT-2 stimulates endogenous oxytocin release from hypothalamic neurons.

A 2019 study in PLOS One showed 7-day MT-2 infusion improved social behaviors in a mouse model of autism via MC4R-mediated oxytocin pathways. SFARI has funded further melanocortin agonist evaluation for social cognition.

Users sometimes report improved mood and sociability while running MT-2. These reports are mixed and hard to separate from the confidence effects of looking tanned and feeling stronger libido. Firmly in the “interesting but unproven in humans” category.

Melanotan 2 vs PT-141 vs Afamelanotide

All three trace back to the same University of Arizona program. MT-2 is the parent compound. PT-141 (bremelanotide) is an active metabolite developed to isolate sexual function effects.

Afamelanotide (Scenesse) is Melanotan 1, the linear version targeting MC1R selectively.

If you want tanning plus sexual function and appetite effects in one compound, MT-2 is the only option that hits all three. PT-141 is better if sexual function is the sole goal. Afamelanotide costs roughly $147,000 per year and is limited to EPP patients.

Dosing Protocol

The original Phase I trial by Dorr and colleagues used 0.025 mg/kg as the reference dose, roughly 1.75mg for a 70kg person. That produced results but also caused significant nausea, so the community has refined dosing over two decades.

Loading Phase

Start at 0.25mg (250 mcg) daily for 3 to 5 days. This is well below the clinical trial dose and dramatically reduces MC4R-driven nausea.

Increase by 0.1mg every 2 to 3 days as tolerated. Most people settle at 0.5mg daily during loading. Some go to 1.0mg, but the side effect profile escalates without proportional benefit.

Loading runs 2 to 4 weeks depending on Fitzpatrick skin type. Fair-skinned individuals (Types I and II) need longer. Types III and IV respond faster, sometimes within 7 to 10 days.

A single 10mg vial from Paramount Peptides covers most of a loading cycle at 0.5mg daily.

Maintenance Phase

Once desired pigmentation is reached, reduce to 0.5mg once or twice weekly. The tan persists 4 to 8 weeks after the last injection even without maintenance.

Many users report subsequent cycles are faster and require less product than the initial cycle.

Injectable vs Nasal Spray

Research protocols use subcutaneous injection. SC bioavailability is essentially 100%. Nasal spray bioavailability is estimated at only 20 to 40% of SC.

That means you need 2 to 3 times the product for equivalent effects. Absorption varies with congestion, and the nasal spray market carries substantially higher contamination risk. Stick with injectable from a tested source like Paramount Peptides (code BRAINFLOW saves 10%).

Reconstitution and Timing

Add 2 mL bacteriostatic water to a 10mg vial for a concentration of 5 mg/mL. At that ratio, 0.1 mL (10 units on a U-100 insulin syringe) equals 0.5mg.

Inject water slowly down the vial wall and gently swirl. Never shake. Store reconstituted vials at 2 to 8°C and use within 4 to 6 weeks.

Inject before bed. Nausea and flushing peak 30 to 90 minutes post-injection. Sleeping through that window is the single most effective side effect management strategy and the near-universal community recommendation.

Some users pre-dose with an antihistamine like fexofenadine (180mg) about 45 minutes prior to further reduce flushing. The mechanism is plausible since MC1R activation triggers histamine release, though this approach has not been formally studied with MT-2.

Research protocols and community consensus both support 4 to 6 week loading cycles. Seasonal users typically load in spring, maintain through summer, and stop in early fall. The tan fades gradually over the following 4 to 8 weeks.

Side Effects: The Real Picture

MT-2’s side effect profile is well-characterized by both clinical data and two decades of community use. Most effects are dose-dependent, transient, and manageable. One requires genuine attention.

Nausea is the most commonly reported side effect. In the Wessells et al. pooled data, nausea occurred with 38% of MT-2 injections, with severe nausea in about 15%.

Most researchers attribute this to MC4R activation in the brainstem rather than MC1R, which is why lower starting doses dramatically cut down on it. Users consistently report that nausea fades after the first 1 to 2 weeks as tolerance develops.

Facial flushing affects 50 to 60% of users via MC1R-mediated vasodilation. It is harmless and resolves within 1 to 2 hours.

Spontaneous erections were documented in 85% of male research subjects in the combined Wessells data. For those using MT-2 primarily for tanning, this is a notable side effect. For those interested in sexual function, it is the primary feature.

Appetite suppression is consistent in both clinical documentation and user reports. It tends to be most pronounced during loading and moderate during maintenance.

Yawning and fatigue are commonly reported, attributed to central MC4R activation. These typically occur in the first hour post-injection.

Blood pressure effects are mild and transient at standard doses per Dorr et al. (1996). Significant cardiovascular effects were only observed in overdose cases.

Mole Darkening and the Melanoma Question

This is the side effect that deserves real attention and an honest answer.

MT-2 darkens existing moles and nevi. This is documented across multiple case reports and is essentially universal among users. Some individuals also develop new nevi during use.

The melanoma question: does stimulating melanocyte activity increase melanoma risk? At least 6 to 7 published case reports link MT-2 use temporally to melanoma, including Hjuler and Lorentzen (2014) documenting melanoma in a 20-year-old woman after 3 months of MT-2.

Every single published case had additional confounding risk factors: fair skin, tanning bed use, family history, or high-risk genetic variants. A 2021 systematic review concluded the observed risk “can probably be explained by more UV exposure” rather than the peptide itself.

The theoretical mechanism is plausible but causation has not been established. Andrew Huberman has addressed this concern when discussing melanocortin peptides, recommending baseline skin assessment for anyone considering MC1R agonists.

The responsible approach is not to dismiss this concern and not to overstate it. It is to manage it with baseline documentation and monthly checks.

Who Should Avoid Melanotan 2

MT-2 is not appropriate for everyone. The following are clear contraindications based on the pharmacological profile and published case data:

• Personal or family history of melanoma or atypical mole syndrome
• Dysplastic nevus syndrome, CDKN2A or MC1R loss-of-function genetic variants
• More than 50 moles or a high burden of atypical nevi
• Pregnancy or breastfeeding (zero safety data exists)
• Cardiovascular conditions given documented hypertension and tachycardia in overdose cases
• History of priapism or concurrent PDE5 inhibitor use (additive erectile effects)

Skin Safety and Mole Monitoring

This is the single most legitimate safety measure for anyone using a melanocortin agonist. The dermatology literature is consistent on what responsible use looks like.

Before starting MT-2, document your baseline. Ideally this means a full-body dermatoscopic exam. At minimum, take high-resolution photographs of all existing moles.

Use the ABCDE criteria for ongoing monitoring. Asymmetry, Border irregularity, Color variation, Diameter over 6mm, and Evolution of any characteristic. Any mole showing one or more of these changes warrants professional evaluation.

Check monthly during active use and for 3 months after stopping. MT-2 darkens all melanocytic lesions, which can make monitoring harder.

One case report noted that MT-2-induced changes can mimic melanoma on dermoscopy, increasing biopsy rates. This is inconvenient but not dangerous if you are monitoring proactively.

Frame this the same way you would blood work before and during a hormone protocol. It takes 10 minutes a month and eliminates the primary risk concern.

Melanotan 2 vs Tanning Beds and Spray Tans

Tanning beds deliver UV radiation directly to skin, causing DNA damage via thymine dimer formation. The AAD estimates a 59% increased melanoma risk from tanning bed use before age 35.

MT-2 specifically increases eumelanin, the protective brown-black pigment. The Barnetson et al. study showed a 59% reduction in thymine dimers with melanotropin use, suggesting genuine DNA damage protection.

Users still need some UV to activate and distribute the pigment, but far less of it. Community consensus is 10 to 15 minutes of moderate sun every 2 to 3 days during loading.

Spray tans use dihydroxyacetone (DHA), which reacts with dead skin cells to form melanoidins. These are cosmetic polymers, not melanin. They provide zero UV protection and last 5 to 10 days.

The MT-2 tan is real eumelanin that lasts weeks to months and costs $120 to $300 per year. Users who have tried all three consistently rate MT-2 as the most natural-looking option.

The practical calculation for most users: MT-2 with 10 to 15 minutes of sun every few days achieves a deeper, longer-lasting tan than either weekly tanning bed sessions or biweekly spray tans. The UV exposure is a fraction of what tanning beds deliver. And the result is actual protective pigment rather than a cosmetic coating that washes off.

Stacking Melanotan 2 with Other Peptides

MT-2 is most commonly run standalone. The community does not report significant synergistic benefits from stacking it with other compounds for its primary effects.

Some users run MT-2 alongside BPC-157 for tissue repair during active training phases, taking advantage of the appetite suppression for cutting. Others include it during growth hormone secretagogue protocols with tesamorelin.

There are no documented interactions between MT-2 and other research peptides like BPC-157 or GHK-Cu, since they operate through entirely different receptor systems. The main practical consideration is injection timing and site rotation if running multiple peptides.

For a broader overview of peptide protocol combinations, our peptides for men guide covers common stacking strategies.

Where to Buy Melanotan 2

Purity matters more with MT-2 than with most research peptides. This compound directly activates melanocytes. Unknown impurities interacting with those cells is a risk you can control.

A 2015 analytical study by Breindahl et al. tested 26 vials from 3 online vendors claiming 10mg per vial. Actual content ranged from only 4.32 to 8.84mg, with some containing barely 43% of the labeled amount.

Other seized samples have been found to contain arsenic, lead, and microbial contamination. A BBC investigation found products with over 100 unidentified ingredients. This is not a category where saving $15 on a cheaper vendor makes sense.

Our recommendation is Paramount Peptides. They synthesize in-house in Southern California, have operated for over 12 years, verify at 99%+ purity via HPLC and mass spectrometry, and provide batch-specific COAs. Code BRAINFLOW saves 10%.

Frequently Asked Questions

Does Melanotan 2 cause cancer?

The research does not establish that MT-2 causes melanoma. At least 6 to 7 case reports document melanoma in MT-2 users, but every case involved additional risk factors like fair skin, tanning bed use, or genetic variants.

A 2021 systematic review attributed the observed risk to increased UV exposure rather than the peptide. The theoretical concern is real because MT-2 stimulates melanocyte proliferation, but causation has not been proven.

Interestingly, a 2020 in vivo study actually found MT-2 suppressed melanoma progression in an animal model. The evidence actually conflicts on this point. Get a baseline skin check, monitor moles monthly, and avoid excessive UV.

How long does an MT-2 tan last after stopping?

Most users report pigmentation persists 4 to 8 weeks after the last injection, fading gradually. The tan fades because melanin-containing keratinocytes shed through normal skin turnover over roughly 28 days.

Freckles and high-melanocyte-density areas retain color longer. Subsequent cycles tend to produce faster results, as though the melanocytes remain primed.

Does MT-2 work without UV exposure?

The 1996 Dorr trial showed some tanning from MT-2 alone without intentional UV exposure. But results are dramatically better with even brief sun, because UV upregulates MC1R expression on melanocytes.

Community consensus is 10 to 15 minutes of natural sun every 2 to 3 days during loading. Excessive UV on MT-2 can cause uneven pigmentation.

Is Melanotan 2 legal?

MT-2 is not FDA-approved. It sits on the FDA Category 2 “do not compound” list as of late 2023 and was not reclassified in the February 2026 HHS announcement. It is not a DEA-scheduled controlled substance.

In the US, personal possession is a legal gray area. In the UK, sale and supply are illegal. In Australia, the TGA actively seizes shipments.

No country has formally scheduled it as a controlled substance in the traditional narcotics sense.

How does MT-2 compare to tanning beds?

MT-2 increases eumelanin production with measurable DNA damage reduction per the clinical data. Tanning beds deliver cumulative UV radiation that increases melanoma risk by an estimated 59% when used before age 35.

Both carry risks, but the profiles are different. Users still need some UV while on MT-2, but far less than a typical tanning bed protocol requires.

How long before results show?

Most users report visible darkening within 4 to 7 days, with freckles responding first. Significant tanning typically develops by weeks 2 to 3.

Fair-skinned individuals (Fitzpatrick I and II) take longer. Olive-skinned users (Types III and IV) can see results in under a week. The GHK-Cu guide covers a complementary skin health peptide through a different mechanism.

Can women use Melanotan 2?

Yes. Women respond at similar or lower doses for tanning. Sexual side effects in women are well-documented, including heightened arousal and enhanced orgasmic intensity.

This directly led to Vyleesi’s development, approved for women with HSDD based on Phase III trials involving over 1,200 participants. Pregnancy is a firm contraindication.

What is the difference between Melanotan 1 and Melanotan 2?

Melanotan 1 (afamelanotide) is the linear 13-amino-acid version targeting MC1R more selectively. It produces tanning without significant sexual or appetite effects because it does not cross the blood-brain barrier.

It was FDA-approved as Scenesse in 2019 for erythropoietic protoporphyria at roughly $49,000 per implant. MT-2 is cheaper, faster-acting, and delivers the libido and appetite effects. The tradeoff is a broader side effect profile.

Final Verdict

MT-2 has a small but remarkably consistent clinical evidence base. The tanning data goes back nearly 30 years. The sexual function research produced an 85% response rate and led directly to an FDA-approved drug.

Appetite suppression is documented in every trial and validated by the broader melanocortin receptor literature. The melanocortin pathway itself is now responsible for three FDA-approved drugs: Vyleesi for sexual dysfunction, Scenesse for EPP, and Imcivree for genetic obesity.

The tradeoffs are real. Nausea during loading is common at higher doses, though manageable with low starting doses and bedtime injection. The mole monitoring requirement is non-negotiable.

Product quality varies widely across vendors, making source selection critical. We use and recommend Paramount Peptides for MT-2 specifically because of the purity stakes involved with melanocyte activation. Code BRAINFLOW saves 10%.

Users who benefit most are fair-to-medium-skinned individuals who want a real melanin tan with less UV, people seeking combined tanning and libido effects, and those who value appetite suppression during a cut. If tanning alone is the goal and the sexual effects are unwanted, there is no way to separate them with MT-2.

If you want all three effects from a single compound, MT-2 is the only research peptide that delivers. The evidence supports it, two decades of community data confirms it, and the science behind it produced two FDA-approved drugs.

Related Reading

• PT-141 Peptide Guide: Benefits, Dosing, and How It Works
• Best Peptides for Men in 2026
• Andrew Huberman’s Peptide Protocols

Melanotan 2 is not FDA-approved for any indication. All information in this article is provided for educational and research purposes only and does not constitute medical advice.

MT-2 is sold as a research peptide for laboratory use only. Consult a qualified healthcare provider before beginning any peptide protocol.

This article contains affiliate links to Paramount Peptides. BrainFlow may earn a commission on qualifying purchases at no additional cost to the reader. We only recommend products and sources we trust.